MCID: PRV006
MIFTS: 53

Pervasive Developmental Disorder

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Pervasive Developmental Disorder

MalaCards integrated aliases for Pervasive Developmental Disorder:

Name: Pervasive Developmental Disorder 12 55 15
Pervasive Development Disorder 12 73
Pervasive Developmental Disorders 54
Autism Spectrum Disorders 73
Autistic Behavior 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0060040
ICD9CM 35 299.80
ICD10 33 F84

Summaries for Pervasive Developmental Disorder

NINDS : 54 The diagnostic category of pervasive developmental disorders (PDD) refers to a group of disorders characterized by delays in the development of socialization and communication skills. Parents may note symptoms as early as infancy, although the typical age of onset is before 3 years of age. Symptoms may include problems with using and understanding language; difficulty relating to people, objects, and events; unusual play with toys and other objects; difficulty with changes in routine or familiar surroundings, and repetitive body movements or behavior patterns. Autism (a developmental brain disorder characterized by impaired social interaction and communication skills, and a limited range of activities and interests) is the most characteristic and best studied PDD. Other types of PDD include Asperger's Syndrome, Childhood Disintegrative Disorder, and Rett's Syndrome. Children with PDD vary widely in abilities, intelligence, and behaviors. Some children do not speak at all, others speak in limited phrases or conversations, and some have relatively normal language development. Repetitive play skills and limited social skills are generally evident. Unusual responses to sensory information, such as loud noises and lights, are also common.

MalaCards based summary : Pervasive Developmental Disorder, also known as pervasive development disorder, is related to autism spectrum disorder and childhood disintegrative disease, and has symptoms including photophobia, restlessness and personality changes. An important gene associated with Pervasive Developmental Disorder is MECP2 (Methyl-CpG Binding Protein 2), and among its related pathways/superpathways are Neuroscience and Transmission across Chemical Synapses. The drugs Oxytocin and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and testes, and related phenotypes are Decreased viability after Maraba virus infection and Decreased viability after Maraba virus infection

Disease Ontology : 12 A developmental disorder of mental health that refers to a group of five disorders characterized by impairments in socialization and communication, as well as restricted interests and repetitive behaviors.

Wikipedia : 76 The diagnostic category pervasive developmental disorders (PDD), as opposed to specific developmental... more...

Related Diseases for Pervasive Developmental Disorder

Diseases related to Pervasive Developmental Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Related Disease Score Top Affiliating Genes
1 autism spectrum disorder 32.7 CHD8 CNTNAP2 FOXP2 GABRB3 MECP2 NLGN3
2 childhood disintegrative disease 32.3 GABRB3 SHANK3
3 asperger syndrome 32.2 GABRB3 MECP2 NLGN3 NLGN4X SHANK3 SLC6A4
4 autism 31.8 CHD8 CNTNAP2 CTNND2 EIF4E FOXP2 GABRB3
5 specific developmental disorder 31.7 FOXP2 MECP2 SHANK3 SLC6A4
6 attention deficit-hyperactivity disorder 31.0 CNTNAP2 MECP2 NLGN4X SLC6A4 SLC9A9 TDO2
7 mutism 30.3 CNTNAP2 SHANK3
8 fragile x syndrome 30.2 EIF4E MECP2 SLC6A4
9 landau-kleffner syndrome 11.3
10 autism x-linked 1 11.2
11 autism x-linked 2 11.2
12 autism x-linked 3 11.2
13 autism x-linked 4 11.2
14 autism x-linked 5 11.2
15 autism x-linked 6 11.2
16 autism 15 11.2
17 autism 16 11.2
18 autism 17 11.2
19 autism 18 11.2
20 autism 5 11.1
21 autism 8 11.1
22 autism 3 11.1
23 autism 6 11.1
24 autism 7 11.1
25 autism 11 11.1
26 autism 12 11.1
27 potocki-lupski syndrome 11.1
28 autism 13 11.1
29 autism 9 11.1
30 autism 10 11.1
31 chromosome 16p11.2 deletion syndrome, 220-kb 11.0
32 autism 19 11.0
33 mental retardation, autosomal recessive 41 11.0
34 atypical autism 10.9
35 rett syndrome 10.9
36 epilepsy 10.5
37 anxiety 10.3
38 mental retardation, autosomal dominant 26 10.3
39 schizophrenia 10.3
40 bipolar disorder 10.3
41 x-linked non-specific intellectual disability 10.2 MECP2 NLGN4X PTCHD1
42 gilles de la tourette syndrome 10.2
43 colitis 10.2
44 hyperlexia 10.1
45 alacrima, achalasia, and mental retardation syndrome 10.1
46 speech and communication disorders 10.1 CNTNAP2 FOXP2 MECP2 TOR3A
47 disease of mental health 10.1 MECP2 SHANK3 SLC6A4 TOR3A
48 psychotic disorder 10.1 GABRB3 SHANK3 SLC6A4
49 articulation disorder 10.1 CNTNAP2 FOXP2
50 angelman syndrome 10.0

Graphical network of the top 20 diseases related to Pervasive Developmental Disorder:



Diseases related to Pervasive Developmental Disorder

Symptoms & Phenotypes for Pervasive Developmental Disorder

UMLS symptoms related to Pervasive Developmental Disorder:


photophobia, restlessness, personality changes, pseudobulbar behavioral symptoms, sleep disturbances

GenomeRNAi Phenotypes related to Pervasive Developmental Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability after Maraba virus infection GR00252-A-1 9.74 CHD8 FOXP2 GABRB3 PTCHD1 SCT SHANK2
2 Decreased viability after Maraba virus infection GR00252-A-2 9.74 CHD8 FOXP2 GABRB3 PTCHD1 SCT SHANK2
3 Decreased viability after Maraba virus infection GR00252-A-3 9.74 FOXP2

MGI Mouse Phenotypes related to Pervasive Developmental Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.77 CHD8 CNTNAP2 CTNND2 GABRB3 KCND2 MECP2
2 nervous system MP:0003631 9.44 CHD8 CNTNAP2 CTNND2 GABRB3 KCND2 MECP2

Drugs & Therapeutics for Pervasive Developmental Disorder

Drugs for Pervasive Developmental Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 325)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxytocin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-56-6 439302 53477758
2
Donepezil Approved Phase 4,Phase 1,Phase 2 120014-06-4 3152
3
Acetylcholine Approved Phase 4,Phase 1 51-84-3 187
4
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2 129722-12-9 60795
5
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
6
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 113-45-1 4158
7
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 19982-08-2 4054
8
Guanfacine Approved, Investigational Phase 4,Not Applicable 29110-47-2 3519
9
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
10
Acetylcysteine Approved, Investigational Phase 4,Phase 2 616-91-1 12035
11
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
12
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106266-06-2 5073
13
Olanzapine Approved, Investigational Phase 4,Phase 2 132539-06-1 4585
14
Buspirone Approved, Investigational Phase 4,Phase 2,Not Applicable 36505-84-7 2477
15
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
16
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
17
Choline Approved, Nutraceutical Phase 4 62-49-7 305
18
Melatonin Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 73-31-4 896
19 Oxytocics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Vasodilator Agents Phase 4,Phase 2,Not Applicable,Early Phase 1
22 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Nootropic Agents Phase 4,Phase 3,Phase 1,Phase 2
24 Cholinesterase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
25 Antimetabolites Phase 4,Phase 3
26 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
28 Lipid Regulating Agents Phase 4
29 Hypolipidemic Agents Phase 4
30 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
34 Immunologic Factors Phase 4,Phase 2
35 Immunoglobulins Phase 4
36 Immunoglobulins, Intravenous Phase 4
37 gamma-Globulins Phase 4
38 Antibodies Phase 4
39 Rho(D) Immune Globulin Phase 4
40 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
41 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Omega 3 Fatty Acid Phase 4,Phase 2,Not Applicable
43 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
44 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Antiviral Agents Phase 4,Phase 2
47 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Antioxidants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
49 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
50 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 775)
# Name Status NCT ID Phase Drugs
1 Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders Unknown status NCT02940574 Phase 4 Syntocinon (Oxytocin)
2 Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders Unknown status NCT01098383 Phase 4 Acetyl-Choline Esterase Inhibitors and Choline supplements;Indistinguishable placebo tablets, matching both donepezil and choline
3 Study to Evaluate the Efficacy and Safety of Aripiprazole Unknown status NCT02069977 Phase 4 Aripiprazole
4 An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum Unknown status NCT02199925 Phase 4 Gammaplex 5%
5 A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders Completed NCT01333865 Phase 4 Memantine
6 FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders Completed NCT01028820 Phase 4 Aripiprazole
7 Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder Completed NCT01238575 Phase 4 extended-release guanfacine
8 Omega-3 Fatty Acids in Autism Spectrum Disorders Completed NCT01695200 Phase 4
9 Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD Completed NCT02096952 Phase 4 Methylphenidate extended-release liquid formulation
10 Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder Completed NCT00380692 Phase 4 Atomoxetine;Placebo
11 Atomoxetine, Placebo and Parent Management Training in Autism Completed NCT00844753 Phase 4 atomoxetine;Placebo
12 Preemie Tots: A Pilot Study to Understand the Effects of Prematurity in Toddlerhood Completed NCT01683565 Phase 4 LCPUFA oil supplement
13 Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study Completed NCT02255565 Phase 4 Very Low Dose Quillivant XR;Low Dose Quillivant XR;Moderate Dose Quillivant XR
14 Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism Completed NCT01337700 Phase 4 Milnacipran;Placebo
15 Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism Completed NCT02235467 Phase 4
16 A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD Completed NCT00485849 Phase 4 Atomoxetine Hydrochloride
17 The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia Completed NCT01339858 Phase 4 N-Acetyl Cysteine
18 An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications. Completed NCT00391261 Phase 4 Metformin
19 Metabolic Effects of Antipsychotics in Children Completed NCT00205699 Phase 4 risperidone;olanzapine;aripiprazole
20 Improving Driving in Young People With Autism Spectrum Disorders Recruiting NCT03538431 Phase 4 Buspirone
21 Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism Recruiting NCT03337646 Phase 4 Lisdexamfetamine Dimesylate
22 A Multi-site Randomized Controlled Trial Comparing Regional and General Anesthesia for Effects on Neurodevelopmental Outcome and Apnea in Infants Active, not recruiting NCT00756600 Phase 4 Regional Anesthesia;General Anesthesia
23 Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes Enrolling by invitation NCT03333629 Phase 4
24 Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD) Using Telepsychiatry of Complementary and Alternative Treatments Not yet recruiting NCT03757585 Phase 4 Open-label Treatment with Omega-3 Fatty Acids + Inositol;Open-label Treatment with N-Acetyl Cysteine
25 Melatonin CR for the Treatment of Impaired Sleep Maintenance in 4-8 Year Old Children With Autism Spectrum Disorders Terminated NCT01033565 Phase 4 Natrol
26 Group Psychoeducational Program for Mothers of Children With High Functional Pervasive Developmental Disorders Unknown status NCT01243905 Phase 2, Phase 3
27 Verification of the Efficacy of NPC-15 for Sleep Disorders of Children With Autism Spectrum Disorders Unknown status NCT02757066 Phase 2, Phase 3 NPC-15 Granules Lower Dose;NPC-15 Granules Higher Dose;NPC-15 Placebo Granule
28 Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders Completed NCT00870727 Phase 3 Aripiprazole oral product;Placebo oral capsule
29 Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders Completed NCT01302964 Phase 3 Placebo;Mirtazapine
30 D-Cycloserine and Social Skills Training in Autism Spectrum Disorders Completed NCT01086475 Phase 3 D-cycloserine;Placebo
31 Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder Completed NCT01972074 Phase 3 Memantine;Placebo
32 Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders Completed NCT02081027 Phase 2, Phase 3 Riluzole;placebo
33 A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD) Completed NCT00261508 Phase 3 risperidone
34 Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD) Completed NCT01825798 Phase 3 Metformin;Placebo
35 Folinic Acid in Autism Completed NCT03771560 Phase 2, Phase 3 folinic acid
36 Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders Completed NCT01178385 Phase 2, Phase 3
37 Use of Acupuncture In Children With Autistic Spectrum Disorder Completed NCT00346736 Phase 3
38 Use of Acupuncture In Children With Autistic Spectrum Disorder Completed NCT00352352 Phase 3
39 Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder Completed NCT00352248 Phase 3
40 Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation Completed NCT00355329 Phase 3
41 Acamprosate in Youth With Fragile X Syndrome Completed NCT01300923 Phase 3 Acamprosate
42 Supporting the Well Being of Families of Young Children With Autism Spectrum Disorders Completed NCT01021384 Phase 3
43 Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism Completed NCT00498173 Phase 3 Atomoxetine;Placebo
44 A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms Completed NCT00541346 Phase 3 Methylphenidate Transdermal System
45 Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism Completed NCT01039792 Phase 2, Phase 3 Methyl B12
46 Study of Paliperidone ER in Adolescents and Young Adults With Autism Completed NCT00549562 Phase 3 Paliperidone ER
47 Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD) Completed NCT00337571 Phase 3 Aripiprazole;Placebo
48 Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD) Completed NCT00332241 Phase 3 Aripiprazole;Placebo
49 Galantamine Versus Placebo in Childhood Autism Completed NCT00252603 Phase 3 Galantamine
50 Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome Completed NCT01282268 Phase 3 arbaclofen;placebo

Search NIH Clinical Center for Pervasive Developmental Disorder

Genetic Tests for Pervasive Developmental Disorder

Anatomical Context for Pervasive Developmental Disorder

MalaCards organs/tissues related to Pervasive Developmental Disorder:

41
Brain, Liver, Testes, Eye, Skin, Heart, Cortex

Publications for Pervasive Developmental Disorder

Articles related to Pervasive Developmental Disorder:

(show top 50) (show all 251)
# Title Authors Year
1
Neonatal factors among subjects diagnosed with a pervasive developmental disorder in the US. ( 28462601 )
2017
2
Autism Spectrum/Pervasive Developmental Disorder. ( 27262008 )
2016
3
Are There Differences in Neurocognition and Social Cognition Among Adolescents with Schizophrenia, a Pervasive Developmental Disorder, and Both Disorders? ( 27015370 )
2016
4
Hemispheric Processing of Idioms and Irony in Adults With and Without Pervasive Developmental Disorder. ( 26070277 )
2015
5
A Prospective Longitudinal Assessment of Medical Records for Diagnostic Substitution among Subjects Diagnosed with a Pervasive Developmental Disorder in the United States. ( 26528457 )
2015
6
The Stability of Comorbid Psychiatric Disorders: A 7 Year Follow Up of Children with Pervasive Developmental Disorder-Not Otherwise Specified. ( 26456972 )
2015
7
Examining the criterion-related validity of the Pervasive Developmental Disorder Behavior Inventory. ( 24463433 )
2014
8
Effect of levetiracetam on behavioral problems in pervasive developmental disorder children with epilepsy. ( 24703761 )
2014
9
Psychiatric comorbidity in children with high-functioning pervasive developmental disorder. ( 25272562 )
2014
10
Detecting Subgroups in Children Diagnosed with Pervasive Developmental Disorder - Not Otherwise Specified. ( 25374133 )
2014
11
A comparison of DSM-IV pervasive developmental disorder and DSM-5 autism spectrum disorder prevalence in an epidemiologic sample. ( 24745950 )
2014
12
Sunsetting DSM-IV's pervasive developmental disorder. ( 24745948 )
2014
13
Psychological interventions in pervasive developmental disorder: An overview. ( 25788797 )
2014
14
Sensory hypersensitivity in children with high-functioning pervasive developmental disorder. ( 25803881 )
2014
15
A Case-Control Study Evaluating the Relationship Between Thimerosal-Containing Haemophilus influenzae Type b Vaccine Administration and the Risk for a Pervasive Developmental Disorder Diagnosis in the United States. ( 25382662 )
2014
16
Catatonic features in adolescents with schizophrenia with and without a comorbid pervasive developmental disorder. ( 24914405 )
2014
17
Diagnostic Boundaries of Autism Disorder Vs Pervasive Developmental Disorder Nos: Comparative Observational Study and Literature Review. ( 24050746 )
2013
18
Brief report: An unusual manifestation of diagnostic overshadowing of pervasive developmental disorder--not otherwise specified: a five year longitudinal case study. ( 23108987 )
2013
19
Comparison of pervasive developmental disorder and schizophrenia by the Japanese version of the National Adult Reading Test. ( 22335467 )
2013
20
Psychiatric diagnostic screening of social maladaptive behaviour in children with mild intellectual disability: differentiating disordered attachment and pervasive developmental disorder behaviour. ( 23906477 )
2013
21
Reduced brain activation during imitation and observation of others in children with pervasive developmental disorder: a pilot study. ( 23718943 )
2013
22
Dual copy number variants involving 16p11 and 6q22 in a case of childhood apraxia of speech and pervasive developmental disorder. ( 22909776 )
2013
23
Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified. ( 24130822 )
2013
24
Pervasive developmental disorder in the children of immigrant parents: comparison of different assessment instruments. ( 24394875 )
2013
25
Anxiety in children with high-functioning pervasive developmental disorder. ( 23909078 )
2013
26
Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study. ( 23782127 )
2013
27
Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger's disorder: a 12-week prospective, open-label study. ( 23194148 )
2012
28
Sexual obsessions, compulsions, suicidality and homicidality in an adolescent diagnosed with bipolar disorder not otherwise specified, obsessive-compulsive disorder, pervasive developmental disorder not otherwise specified, and mild mental retardation. ( 22612525 )
2012
29
Executive function in children with pervasive developmental disorder and attention-deficit/hyperactivity disorder assessed by the Keio version of the Wisconsin card sorting test. ( 21917389 )
2012
30
A case of autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) coexisting with pervasive developmental disorder harboring SCN1A mutation in addition to CHRNB2 mutation. ( 23032131 )
2012
31
Is recovery from a pervasive developmental disorder possible? ( 22353321 )
2012
32
Is long-term prognosis for pervasive developmental disorder not otherwise specified different from prognosis for autistic disorder? Findings from a 30-year follow-up study. ( 21713590 )
2012
33
Using virtual reality environment to improve joint attention associated with pervasive developmental disorder. ( 22776822 )
2012
34
Novel AGTR2 missense mutation in a Japanese boy with severe mental retardation, pervasive developmental disorder, and epilepsy. ( 22269148 )
2012
35
Focal EEG abnormalities might reflect neuropathological characteristics of pervasive developmental disorder and attention-deficit/hyperactivity disorder. ( 22225922 )
2012
36
Multi-channel near-infrared spectroscopy shows reduced activation in the prefrontal cortex during facial expression processing in pervasive developmental disorder. ( 22250607 )
2012
37
Brief report: prevalence of pervasive developmental disorder in Brazil: a pilot study. ( 21337063 )
2011
38
Possible evidence for a fall in the prevalence of high-functioning pervasive developmental disorder with age? ( 22937245 )
2011
39
Toward specifying pervasive developmental disorder-not otherwise specified. ( 21298812 )
2011
40
New onset of psychotic symptoms in an adolescent with pervasive developmental disorder, not otherwise specified. ( 21309699 )
2011
41
Analysis of Copper and Zinc Plasma Concentration and the Efficacy of Zinc Therapy in Individuals with Asperger's Syndrome, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) and Autism. ( 22174567 )
2011
42
The specific impairment of fearful expression recognition and its atypical development in pervasive developmental disorder. ( 21919566 )
2011
43
Liquid melatonin via gastrostomy as an alternative hypnotic in a child with pervasive developmental disorder. ( 21663434 )
2011
44
Evaluation of oxidative stress status in children with pervasive developmental disorder and attention deficit hyperactivity disorder using urinary-specific biomarkers. ( 21605498 )
2011
45
Retrospective case report: evaluation of pain in a child with pervasive developmental disorder. ( 21552087 )
2011
46
Buspirone for bruxism in a child with pervasive developmental disorder-not otherwise specified. ( 22136097 )
2011
47
Epilepsy in pervasive developmental disorder without brain MRI abnormalities. ( 20863637 )
2011
48
Abnormal brain protein synthesis in language areas of children with pervasive developmental disorder: a L-[1-11C]-leucine PET study. ( 21636781 )
2011
49
Is pervasive developmental disorder not otherwise specified less stable than autistic disorder? A meta-analysis. ( 21153874 )
2011
50
Effectiveness of modified parent training for mothers of children with Pervasive Developmental Disorder on parental confidence and children's behavior. ( 20385459 )
2011

Variations for Pervasive Developmental Disorder

ClinVar genetic disease variations for Pervasive Developmental Disorder:

6 (show all 44)
# Gene Variation Type Significance SNP ID Assembly Location
1 ASF1A; CEP85L; DCBLD1; FAM184A; GOPC; MCM9; NUS1; PLN; SLC35F1 NC_000006.11 deletion Pathogenic GRCh37 Chromosome 6, 117810940: 119417749
2 WFS1 NM_006005.3(WFS1): c.2603G> A (p.Arg868His) single nucleotide variant Conflicting interpretations of pathogenicity rs56393026 GRCh38 Chromosome 4, 6302398: 6302398
3 WFS1 NM_006005.3(WFS1): c.2603G> A (p.Arg868His) single nucleotide variant Conflicting interpretations of pathogenicity rs56393026 GRCh37 Chromosome 4, 6304125: 6304125
4 TBR1 NM_006593.3(TBR1): c.1588_1594dupGGCTGCA (p.Thr532Argfs) duplication Likely pathogenic rs869312704 GRCh37 Chromosome 2, 162280277: 162280283
5 TBR1 NM_006593.3(TBR1): c.1588_1594dupGGCTGCA (p.Thr532Argfs) duplication Likely pathogenic rs869312704 GRCh38 Chromosome 2, 161423766: 161423772
6 RSRC2 NM_023012.5(RSRC2): c.425G> A (p.Arg142Gln) single nucleotide variant Likely pathogenic rs752134549 GRCh37 Chromosome 12, 123001951: 123001951
7 RSRC2 NM_023012.5(RSRC2): c.425G> A (p.Arg142Gln) single nucleotide variant Likely pathogenic rs752134549 GRCh38 Chromosome 12, 122517404: 122517404
8 FMR1 NM_002024.5(FMR1): c.199-2A> G single nucleotide variant Likely pathogenic rs1057518850 GRCh37 Chromosome X, 147009838: 147009838
9 FMR1 NM_002024.5(FMR1): c.199-2A> G single nucleotide variant Likely pathogenic rs1057518850 GRCh38 Chromosome X, 147928320: 147928320
10 WFS1 NM_001145853.1(WFS1): c.2540G> A (p.Cys847Tyr) single nucleotide variant Uncertain significance GRCh38 Chromosome 4, 6302335: 6302335
11 WFS1 NM_001145853.1(WFS1): c.2540G> A (p.Cys847Tyr) single nucleotide variant Uncertain significance GRCh37 Chromosome 4, 6304062: 6304062
12 GRIN2B NM_000834.4(GRIN2B): c.2225G> T (p.Arg742Ile) single nucleotide variant Likely pathogenic GRCh38 Chromosome 12, 13569964: 13569964
13 GRIN2B NM_000834.4(GRIN2B): c.2225G> T (p.Arg742Ile) single nucleotide variant Likely pathogenic GRCh37 Chromosome 12, 13722898: 13722898
14 CRACR2A; PARP11; PRMT8; TSPAN9 GRCh37/hg19 12p13.33-13.32(chr12: 3288857-4004582) copy number loss Uncertain significance GRCh37 Chromosome 12, 3288857: 4004582
15 TBR1 NM_006593.3(TBR1): c.471del (p.Tyr157Terfs) deletion Likely pathogenic GRCh38 Chromosome 2, 161416881: 161416881
16 TBR1 NM_006593.3(TBR1): c.471del (p.Tyr157Terfs) deletion Likely pathogenic GRCh37 Chromosome 2, 162273392: 162273392
17 TBR1 NM_006593.3(TBR1): c.673A> T (p.Ile225Phe) single nucleotide variant Likely pathogenic GRCh37 Chromosome 2, 162273594: 162273594
18 TBR1 NM_006593.3(TBR1): c.673A> T (p.Ile225Phe) single nucleotide variant Likely pathogenic GRCh38 Chromosome 2, 161417083: 161417083
19 TBR1 NM_006593.3(TBR1): c.713_719del (p.Ser238Thrfs) deletion Likely pathogenic GRCh38 Chromosome 2, 161417696: 161417702
20 TBR1 NM_006593.3(TBR1): c.713_719del (p.Ser238Thrfs) deletion Likely pathogenic GRCh37 Chromosome 2, 162274207: 162274213
21 TBR1 NM_006593.3(TBR1): c.811T> C (p.Trp271Arg) single nucleotide variant Likely pathogenic GRCh38 Chromosome 2, 161417794: 161417794
22 TBR1 NM_006593.3(TBR1): c.811T> C (p.Trp271Arg) single nucleotide variant Likely pathogenic GRCh37 Chromosome 2, 162274305: 162274305
23 TBR1 NM_006593.3(TBR1): c.844C> T (p.Gln282Ter) single nucleotide variant Likely pathogenic GRCh37 Chromosome 2, 162274338: 162274338
24 TBR1 NM_006593.3(TBR1): c.844C> T (p.Gln282Ter) single nucleotide variant Likely pathogenic GRCh38 Chromosome 2, 161417827: 161417827
25 TBR1 NM_006593.3(TBR1): c.896G> A (p.Trp299Ter) single nucleotide variant Likely pathogenic GRCh38 Chromosome 2, 161418249: 161418249
26 TBR1 NM_006593.3(TBR1): c.896G> A (p.Trp299Ter) single nucleotide variant Likely pathogenic GRCh37 Chromosome 2, 162274760: 162274760
27 TBR1 NM_006593.3(TBR1): c.1155C> G (p.Asn385Lys) single nucleotide variant Likely pathogenic rs762713626 GRCh38 Chromosome 2, 161420222: 161420222
28 TBR1 NM_006593.3(TBR1): c.1155C> G (p.Asn385Lys) single nucleotide variant Likely pathogenic rs762713626 GRCh37 Chromosome 2, 162276733: 162276733
29 TBR1 NM_006593.3(TBR1): c.1177dup (p.Asp393Glyfs) duplication Likely pathogenic GRCh37 Chromosome 2, 162276755: 162276755
30 TBR1 NM_006593.3(TBR1): c.1177dup (p.Asp393Glyfs) duplication Likely pathogenic GRCh38 Chromosome 2, 161420244: 161420244
31 TBR1 NM_006593.3(TBR1): c.1369_1371delACGinsCA (p.Thr457Glnfs) indel Likely pathogenic GRCh37 Chromosome 2, 162280058: 162280060
32 TBR1 NM_006593.3(TBR1): c.1369_1371delACGinsCA (p.Thr457Glnfs) indel Likely pathogenic GRCh38 Chromosome 2, 161423547: 161423549
33 TBR1 NM_006593.3(TBR1): c.1637_1638insCGCCCGCAGT (p.Pro550Argfs) insertion Likely pathogenic GRCh37 Chromosome 2, 162280326: 162280327
34 TBR1 NM_006593.3(TBR1): c.1637_1638insCGCCCGCAGT (p.Pro550Argfs) insertion Likely pathogenic GRCh38 Chromosome 2, 161423815: 161423816
35 TBR1 NM_006593.3(TBR1): c.1653_1654del (p.Gln552Valfs) deletion Likely pathogenic GRCh38 Chromosome 2, 161423831: 161423832
36 TBR1 NM_006593.3(TBR1): c.1653_1654del (p.Gln552Valfs) deletion Likely pathogenic GRCh37 Chromosome 2, 162280342: 162280343
37 subset of 21 genes:SLC4A10; TBR1 NC_000002.11: g.160075929_164666149del4590221 deletion Likely pathogenic GRCh37 Chromosome 2, 160075929: 164666149
38 TBR1 NC_000002.11: g.161561653_163178787del1617135 deletion Likely pathogenic GRCh37 Chromosome 2, 161561653: 163178787
39 TBR1 NC_000002.11: g.161967492_162428730del461239 deletion Likely pathogenic GRCh37 Chromosome 2, 161967492: 162428730
40 CNTN6 NM_014461.3(CNTN6): c.566C> A (p.Ser189Ter) single nucleotide variant Likely pathogenic rs773080572 GRCh37 Chromosome 3, 1337396: 1337396
41 CNTN6 NM_014461.3(CNTN6): c.566C> A (p.Ser189Ter) single nucleotide variant Likely pathogenic rs773080572 GRCh38 Chromosome 3, 1295712: 1295712
42 SND1 NC_000007.13: g.127412602_127569388del156787 deletion Uncertain significance GRCh37 Chromosome 7, 127412602: 127569388
43 ZBTB20 NM_001164342.2(ZBTB20): c.1955A> T (p.His652Leu) single nucleotide variant Likely pathogenic GRCh38 Chromosome 3, 114339276: 114339276
44 ZBTB20 NM_001164342.2(ZBTB20): c.1955A> T (p.His652Leu) single nucleotide variant Likely pathogenic GRCh37 Chromosome 3, 114058123: 114058123

Expression for Pervasive Developmental Disorder

Search GEO for disease gene expression data for Pervasive Developmental Disorder.

Pathways for Pervasive Developmental Disorder

GO Terms for Pervasive Developmental Disorder

Cellular components related to Pervasive Developmental Disorder according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.85 GABRB3 KCND2 NLGN3 NLGN4X SHANK2
2 dendritic spine GO:0043197 9.71 KCND2 SHANK2 SHANK3
3 perikaryon GO:0043204 9.7 CNTNAP2 CTNND2 KCND2
4 presynapse GO:0098793 9.69 NLGN3 NLGN4X SLC6A4
5 postsynapse GO:0098794 9.67 EIF4E MECP2 NLGN3
6 postsynaptic density GO:0014069 9.65 CTNND2 KCND2 NLGN4X SHANK2 SHANK3
7 postsynaptic membrane GO:0045211 9.55 GABRB3 KCND2 NLGN4X SHANK2 SHANK3
8 ionotropic glutamate receptor complex GO:0008328 9.48 SHANK2 SHANK3
9 neuron spine GO:0044309 9.43 SHANK2 SHANK3
10 dendrite GO:0030425 9.43 CNTNAP2 CTNND2 KCND2 NLGN4X SHANK2 SHANK3
11 spanning component of membrane GO:0089717 9.4 NLGN3 NLGN4X
12 asymmetric, glutamatergic, excitatory synapse GO:0098985 9.37 NLGN3 NLGN4X
13 symmetric, GABA-ergic, inhibitory synapse GO:0098983 9.32 NLGN3 NLGN4X
14 cell junction GO:0030054 9.23 CNTNAP2 CTNND2 GABRB3 KCND2 NLGN3 NLGN4X

Biological processes related to Pervasive Developmental Disorder according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 brain development GO:0007420 9.91 CHD8 CNTNAP2 MECP2 SCT SLC6A4
2 cerebellum development GO:0021549 9.75 FOXP2 MECP2 NLGN4X
3 synapse organization GO:0050808 9.73 CTNND2 NLGN3 NLGN4X
4 memory GO:0007613 9.73 MECP2 SHANK2 SHANK3 SLC6A4
5 positive regulation of synaptic transmission, glutamatergic GO:0051968 9.71 NLGN3 SHANK2 SHANK3
6 synapse assembly GO:0007416 9.71 MECP2 NLGN3 SHANK2 SHANK3
7 positive regulation of excitatory postsynaptic potential GO:2000463 9.7 NLGN3 SHANK2 SHANK3
8 regulation of AMPA receptor activity GO:2000311 9.67 NLGN3 SHANK2 SHANK3
9 long-term synaptic potentiation GO:0060291 9.67 MECP2 NLGN3 SHANK2 SHANK3
10 positive regulation of dendritic spine development GO:0060999 9.66 SHANK2 SHANK3
11 long-term synaptic depression GO:0060292 9.65 SHANK2 SHANK3
12 regulation of dendritic spine morphogenesis GO:0061001 9.65 NLGN3 SHANK3
13 startle response GO:0001964 9.65 CHD8 MECP2
14 brain morphogenesis GO:0048854 9.65 SHANK2 SHANK3 SLC6A4
15 adult behavior GO:0030534 9.65 CNTNAP2 NLGN3 NLGN4X SHANK2 SHANK3
16 neuron cell-cell adhesion GO:0007158 9.64 NLGN3 NLGN4X
17 exploration behavior GO:0035640 9.64 SHANK2 SHANK3
18 presynapse assembly GO:0099054 9.63 NLGN3 NLGN4X
19 regulation of respiratory gaseous exchange by neurological system process GO:0002087 9.63 MECP2 NLGN3
20 dendritic spine morphogenesis GO:0060997 9.63 CTNND2 SHANK2 SHANK3
21 learning GO:0007612 9.63 CNTNAP2 MECP2 NLGN3 NLGN4X SHANK2 SHANK3
22 thalamus development GO:0021794 9.62 CNTNAP2 PTCHD1
23 presynaptic membrane assembly GO:0097105 9.62 NLGN3 NLGN4X
24 regulation of long-term synaptic potentiation GO:1900271 9.61 NLGN3 SHANK3
25 inhibitory postsynaptic potential GO:0060080 9.61 GABRB3 NLGN3
26 negative regulation of excitatory postsynaptic potential GO:0090394 9.6 NLGN3 NLGN4X
27 postsynaptic membrane assembly GO:0097104 9.59 NLGN3 NLGN4X
28 positive regulation of AMPA receptor activity GO:2000969 9.58 NLGN3 SHANK3
29 synaptic growth at neuromuscular junction GO:0051124 9.57 SHANK2 SHANK3
30 postsynaptic density assembly GO:0097107 9.55 SHANK2 SHANK3
31 vocal learning GO:0042297 9.5 CNTNAP2 FOXP2 SHANK3
32 vocalization behavior GO:0071625 9.35 CNTNAP2 NLGN3 NLGN4X SHANK2 SHANK3
33 social behavior GO:0035176 9.28 CHD8 CNTNAP2 MECP2 NLGN3 NLGN4X PTCHD1

Molecular functions related to Pervasive Developmental Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor signaling complex scaffold activity GO:0030159 9.37 SHANK2 SHANK3
2 translation regulator activity GO:0045182 9.32 EIF4E RPL10
3 neurexin family protein binding GO:0042043 9.16 NLGN3 NLGN4X
4 scaffold protein binding GO:0097110 9.13 NLGN3 NLGN4X SHANK3
5 GKAP/Homer scaffold activity GO:0030160 8.62 SHANK2 SHANK3
6 protein binding GO:0005515 10.16 CHD8 CNTNAP2 CTNND2 EIF4E FOXP2 KCND2

Sources for Pervasive Developmental Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....